In a double-blind, randomised study of thromboprophylaxis in patients undergoing total hip replacement, we compared a low-molecular-weight heparin with a placebo. Of the 120 patients enrolled, 112 completed the trial; 58 in the treatment group and 54 in the placebo group. Nine (16%) patients in the treatment group and 19 (35%) in the placebo group developed deep venous thrombosis, diagnosed by the 125I-fibrinogen uptake test (p < 0.02). Verification was obtained by phlebography in 86% of the patients. Prolonged surgery increased the risk of thrombosis in the placebo group but not in the treatment group (p < 0.05). There were significantly more cases of deep venous thrombosis in the placebo group during the first four postoperative days (p < 0.02). The groups did not differ with respect to peroperative and postoperative bleeding. Low-molecular-weight heparin offers safe and easily administered thromboprophylaxis in total hip replacement.





Polls results
1

On a scale of 1 to 10, rate how much this article will change your clinical practice?

NO change
BIG change
100% Article relates to my practice (2/2)
0% Article does not relate to my practice (0/2)
0% Undecided (0/2)
2

Will this article lead to more cost-effective healthcare?

50% Yes (1/2)
50% No (1/2)
0% Undecided (0/2)
3

Was this article biased? (commercial or personal)

0% Yes (0/2)
100% No (2/2)
0% Undecided (0/2)
4

What level of evidence do you think this article is?

0% Level 1 (0/2)
0% Level 2 (0/2)
50% Level 3 (1/2)
0% Level 4 (0/2)
50% Level 5 (1/2)